Home » EUROPEAN COMMISSION ISSUES MARKETING AUTHORIZATION FOR PREOTACT
EUROPEAN COMMISSION ISSUES MARKETING AUTHORIZATION FOR PREOTACT
NPS Pharmaceuticals, Inc. and its partner Nycomed announced today that the European Commission has granted marketing authorization for Preotact (parathyroid hormone [rDNA origin] for injection). Preotact is the European brand name for PREOS which
NPS licensed to Nycomed in 2004 for development and marketing in Europe.
CNW Group (http://www.newswire.ca/en/releases/archive/April2006/26/c0830.html)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
07May
-
14May
-
30May